Prostaglandin E receptor subtype EP1 deficiency inhibits colon cancer development

Carcinogenesis

Volumn 26, Issue 2, 2005, Pages 353-357

  Kawamori, Toshihiko ^c,d   Kitamura, Tomohiro ^d   Watanabe, Kouji ^d   Uchiya, Naoaki ^d   Maruyama, Takayuki ^a   Narumiya, Shuh ^b   Sugimura, Takashi ^d   Wakabayashi, Keiji ^d  

^a ONO PHARMACEUTICAL CO   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; EP 1 RECEPTOR; MESSENGER RNA; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTANOID RECEPTOR; PROTEIN KINASE N; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHROMOSOME NOR; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DRUG TARGETING; GENE OVEREXPRESSION; HOMOZYGOSITY; INTESTINE TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SILVER STAINING; TUMOR VOLUME; WILD TYPE;

ADENOCARCINOMA; ADENOMA; ANIMALS; APOPTOSIS; AZOXYMETHANE; CELL PROLIFERATION; COLONIC NEOPLASMS; MICE; MICE, KNOCKOUT; PROTEIN KINASE C; RECEPTORS, PROSTAGLANDIN E;

EID: 13844298698     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh322     Document Type: Article

References (33)

1. Thun,M.J., Namboodiri,M.M. and Heath,C.W.,Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325, 1593-1596.
2. Reddy,B.S., Tokumo,K., Kulkarni,N., Aligia,C. and Kelloff,G. (1992) Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis, 13, 1019-1023.
3. Singh,J., Hamid,R. and Reddy,B.S. (1997) Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res., 57, 3465-3470.
4. Kargman,S.L., O'Neill,G.P., Vickers,P.J., Evans,J.F., Mancini,J.A. and Jothy,S. (1995) Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 55 2556-2559.
5. Sano,H., Kawahito,Y., Wilder,R.L. et al. (1995) Expression of cyclooxygenase-1 and -2 inhuman colorectal cancer. Cancer Res., 55, 3785-3789.
6. Kawamori,T., Rao,C.V., Seibert,K. and Reddy,B.S. (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58, 409-412.
7. Jacoby,R.F., Seibert,K., Cole,C.E., Kelloff,G. and Lubet,R.A. (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res., 60, 5040-5044.
8. Steinbach,G., Lynch,P.M., Phillips,R.K. et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342, 1946-1952.
9. Tsujii,M. and DuBois,R.N. (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83, 493-501.
10. Oshima,M., Dinchuk,J.E., Kargman,S.L., Oshima,H., Hancock,B., Kwong,E., Trzaskos,J.M., Evans,J.F. and Taketo,M.M. (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809.
11. Chulada,P.C., Thompson,M.B., Mahler,J.F. et al. (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res., 60, 4705-4708.
12. Yamaguchi,A., Ishida,T., Nishimura,G., Katoh,M. and Miyazaki,I. (1991) Investigation of colonic prostaglandins in carcinogenesis in the rat colon. Dis. Colon Rectum, 34, 572-576.
13. Rigas,B., Goldman,I.S. and Levine,L. (1993) Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 122 518-523.
14. Kawamori,T., Uchiya,N., Sugimura,T. and Wakabayashi,K. (2003) Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis, 24, 985-990.
15. Ushikubi,F., Segi,E., Sugimoto,Y. et al. (1998) Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature, 395, 281-284.
16. Segi,E., Sugimoto,Y., Yamasaki,A. et al. (1998) Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem. Biophys. Res. Commun., 246, 7-12.
17. Hizaki,H., Segi,E., Sugimoto,Y. et al. (1999) Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). Proc. Natl Acad. Sci. USA, 96, 10501-10506.
18. Watanabe,K., Kawamori,T., Nakatsugi,S. et al. (1999) Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res., 59, 5093-5096.
19. Mutoh,M., Watanabe,K., Kitamura,T. et al. (2002) Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res., 62, 28-32.
20. Mukai,H. and Ono,Y. (1994) A novel protein kinase with leucine zipper-like sequences: its catalytic domain is highly homologous to that of protein kinase C. Biochem. Biophys. Res. Commun., 199 897-904.
21. Batshake,B. and Sundelin,J. (1996) The mouse genes for the EP1 prostanoid receptor and the PKN protein kinase overlap. Biochem. Biophys. Res. Commun., 227, 70-76.
22. Pozharisski,K.M. (1990) Tumours of the intestines. In Turusov,V. and Mohr,U. (eds) Pathology of Tumours in Laboratory Animals, IARC Scientific Publications no. 1. IARC, Lyon, pp. 159-180.
23. Tanaka,T., Takeuchi,T., Nishikawa,A., Takami,T. and Mori,H. (1989) Nucleolar organizer regions in hepatocarcinogenesis induced by N-2-fluorenylacetamide in rats: comparison with bromodeoxyuridine immunohistochemistry. Jpn. J. Cancer Res., 80, 1047-1051.
24. Watabe,A., Sugimoto,Y., Honda,A., Irie,A., Namba,T., Negishi,M., Ito,S., Narumiya,S. and Ichikawa,A. (1993) Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J. Biol. Chem., 268, 20175-20178.
25. Katsuyama,M., Nishigaki,N., Sugimoto,Y., Morimoto,K., Negishi,M., Narumiya,S. and Ichikawa,A. (1995) The mouse prostaglandin E receptor EP2 subtype: cloning, expression and northern blot analysis. FEBS Lett., 372, 151-156.
26. Sugimoto,Y., Negishi,M., Hayashi,Y., Namba,T., Honda,A., Watabe,A., Hirata,M., Narumiya,S. and Ichikawa,A. (1993) Two isoforms of the EP3 receptor with different carboxyl-terminal domains. Identical ligand binding properties and different coupling properties with Gi proteins. J. Biol. Chem., 268, 2712-2718.
27. Honda,A., Sugimoto,Y., Namba,T., Watabe,A., Irie,A., Negishi,M., Narumiya,S. and Ichikawa,A. (1993) Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J. Biol. Chem. 268, 7759-7762.
28. Egan,M.J. and Crocker,J. (1992) Nucleolar organiser regions in pathology. Br. J. Cancer, 65, 1-7.
29. Ruschoff,J., Bittinger,A., Neumann,K. and Schmitz-Moormann,P. (1990) Prognostic significance of nucleolar organizing regions (NORs) in carcinomas of the sigmoid colon and rectum. Pathol. Res. Pract., 186, 85-91.
30. Sonoshita,M., Takaku,K., Sasaki,N., Sugimoto,Y., Ushikubi,F., Narumiya,S., Oshima,M. and Taketo,M.M. (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Ape (Delta 716) knockout mice. Nature Med., 7, 1048-1051.
31. Kotarti,M., Tanaka,I., Ogawa,Y., Usui,T., Tamura,N., Mori,K., Narumiya,S., Yoshimi,T. and Nakao,K. (1997) Structural organization of the human prostaglandin EP3 receptor subtype gene (PTGER3). Genomics 40, 425-434.
32. Namba,T., Sugimoto,Y., Negishi,M., Irie,A., Ushikubi,F., Kakizuka,A., Ito,S., Ichikawa,A. and Narumiya,S. (1993) Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature, 365, 166-170.
33. Negishi,M., Sugimoto,Y., Irie,A., Narumiya,S. and Ichikawa,A. (1993) Two isoforms of prostaglandin E receptor EP3 subtype. Different COOH-terminal domains determine sensitivity to agonist-induced desensitization. J. Biol. Chem., 268, 9517-9521.